EA011618B1 - Применение римонабанта для получения лекарственных средств, пригодных для профилактики и лечения диабета типа 2 - Google Patents

Применение римонабанта для получения лекарственных средств, пригодных для профилактики и лечения диабета типа 2 Download PDF

Info

Publication number
EA011618B1
EA011618B1 EA200701781A EA200701781A EA011618B1 EA 011618 B1 EA011618 B1 EA 011618B1 EA 200701781 A EA200701781 A EA 200701781A EA 200701781 A EA200701781 A EA 200701781A EA 011618 B1 EA011618 B1 EA 011618B1
Authority
EA
Eurasian Patent Office
Prior art keywords
rimonabant
treatment
diabetes
prevention
type
Prior art date
Application number
EA200701781A
Other languages
English (en)
Russian (ru)
Other versions
EA200701781A1 (ru
Inventor
Коринн Анотэн
Пьер Розенцвайг
Original Assignee
Санофи-Авентис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0501861A external-priority patent/FR2882261B1/fr
Application filed by Санофи-Авентис filed Critical Санофи-Авентис
Priority claimed from PCT/FR2006/000376 external-priority patent/WO2006087481A1/fr
Publication of EA200701781A1 publication Critical patent/EA200701781A1/ru
Publication of EA011618B1 publication Critical patent/EA011618B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA200701781A 2005-02-21 2006-02-20 Применение римонабанта для получения лекарственных средств, пригодных для профилактики и лечения диабета типа 2 EA011618B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0501861A FR2882261B1 (fr) 2005-02-21 2005-02-21 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
FR0504942A FR2882264A1 (fr) 2005-02-21 2005-05-12 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
FR0505228A FR2882265B1 (fr) 2005-02-21 2005-05-23 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2.
PCT/FR2006/000376 WO2006087481A1 (fr) 2005-02-21 2006-02-20 Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2

Publications (2)

Publication Number Publication Date
EA200701781A1 EA200701781A1 (ru) 2007-12-28
EA011618B1 true EA011618B1 (ru) 2009-04-28

Family

ID=36809538

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701781A EA011618B1 (ru) 2005-02-21 2006-02-20 Применение римонабанта для получения лекарственных средств, пригодных для профилактики и лечения диабета типа 2

Country Status (10)

Country Link
JP (1) JP2008530189A (ja)
BR (1) BRPI0608183A2 (ja)
CR (1) CR9293A (ja)
EA (1) EA011618B1 (ja)
FR (2) FR2882264A1 (ja)
IL (1) IL185401A0 (ja)
MA (1) MA29262B1 (ja)
MX (1) MX2007009996A (ja)
TN (1) TNSN07297A1 (ja)
TW (1) TW200640457A (ja)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046209A1 (fr) * 1999-02-01 2000-08-10 Sanofi-Synthelabo Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046209A1 (fr) * 1999-02-01 2000-08-10 Sanofi-Synthelabo Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Rimonabant-Studie: Signifikante Verbesserungen der HbA1c-Werte", INTERNET ARTICLE, [Online] XP002339554, Retrieved from the Internet: URL: http: //www. diabetes-news. de/news/nachrichten-2005/pm050617.htm> [retrieved on 2005-08-04], the whole document *
HAMANN A. ET AL.: "Oral diabetes treatment: Which substance is indicated at which time?", INTERNIST 2004 GERMANY, vol. 45, no. 12, 2004, pages 1356-1363, XP002339555, ISSN: 0020-9554, the whole document *
J.-M. M: "Rimonabant: nouvelle classe therapeutique multi-effets en prevention cardiovasculaire", REVUE FRANQAISE DES LABORATOIRES, EDITIONS SCIENTIFIQUES ET MEDICALES ELSEVIER, vol. 2004, no. 367, November 2004 (2004-11), page 11, XP004816553, ISSN: 0338-9898, the whole document *
POIRIER B. ET AL.: "THE ANTI-OBESITY EFFECT OF RIMONABANT IS ASSOCIATED WITH AN IMPROVED SERUM LIPID PROFILE", DIABETES, OBESITY AND METABOLISM, BLACKWELL SCIENCE, OXFORD, GB, vol. 7, no. 1, January 2005 (2005-01), pages 65-72, XP008047132, ISSN: 1462-8902, page 69, column 1, paragraph 1 - column 2, paragraph 1; figure 3 *

Also Published As

Publication number Publication date
FR2882265B1 (fr) 2009-02-13
CR9293A (es) 2007-10-01
MA29262B1 (fr) 2008-02-01
TNSN07297A1 (en) 2008-12-31
BRPI0608183A2 (pt) 2009-11-17
IL185401A0 (en) 2008-08-07
MX2007009996A (es) 2007-10-10
EA200701781A1 (ru) 2007-12-28
TW200640457A (en) 2006-12-01
FR2882264A1 (fr) 2006-08-25
JP2008530189A (ja) 2008-08-07
FR2882265A1 (fr) 2006-08-25

Similar Documents

Publication Publication Date Title
KR101302838B1 (ko) 진성 당뇨병 치료용 로플루밀라스트
EP1377278B1 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
KR101653071B1 (ko) 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
US20130131103A1 (en) Methods and Compositions For Improved Nerve Conduction Velocity
KR20150013838A (ko) 당뇨병 치료를 위한 글루코키나아제 활성화제 조성물
US20080004284A1 (en) Method for treating fibromyalgia syndrome and related conditions
US20180333399A1 (en) Method of improving liver function
KR20230143978A (ko) 시클로-히스프로를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약제학적 제제
JP2009534360A (ja) アルファ−ケトグルタレートを含む組成物およびその筋性能を調節するための使用
WO2003026653A1 (en) Pharmaceutical composition comprising metformin and n-`2-hydroxy-3-(1-piperidinyl)-propoxy! pyridine-1-oxide-3-carboximidoyl chloride
RU2664442C2 (ru) Способ снижения веса
EA011618B1 (ru) Применение римонабанта для получения лекарственных средств, пригодных для профилактики и лечения диабета типа 2
AU2006215444A1 (en) Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes
TWI248814B (en) Compositions comprising D-chiro inositol and lipid lowering compounds
WO2017126524A1 (ja) 糖尿病治療剤の併用
WO2017144978A1 (ru) Соли (1r,2r,3s)-3-(3,4-дихлорфенил)-2-(этоксиметил)-8-метил-8-азабицикло [3.2.1]октана и оптически активных ацетиламинокислот, их применение для лечения ожирения
Whittaker A review of oral diabetic medication
US20040176457A1 (en) Novel NIDDM regimen
KR20070011329A (ko) 인슐린 저항성 개선제를 함유하는 당뇨병 치료제
EP1868598A2 (en) A new dosing regimen for ion channel modulating compounds for treating acute atrial fibrillation in a human
CN101119727A (zh) 利莫那班在制备用于预防和治疗2型糖尿病的药物中的用途
DE102004040630A1 (de) Kombinationstherapie mit Procain
Gordon The person with type 2 diabetes 4
JP2007091641A (ja) ２型糖尿病治療用の併用医薬

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU